Sabra Health Care REIT, Inc. (SBRA) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Hold
Based on 29 analysts4.7% Below Target
SBRA trades 4.7% below Wall Street's consensus target of $21.00.
Current Price$20.06
Average Target$21.00
Target
Current
Low$19.00
Median$21.50
High$22.00
Analyst Target Range
Forward P/E29.7x
(Growth Premium)
PEG Ratio—
Implied Growth+10.6%
(Moderate)
Analyst Spread14.3%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes SBRA achieves its forward estimates and maintains a stable P/E multiple of 29.7x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
SBRA Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Sabra Health Care REIT, Inc. (SBRA) has a Wall Street consensus price target of $21.00, based on estimates from 29 covering analysts. With the stock currently trading at $20.06, this represents a potential upside of +4.7%. The company has a market capitalization of $5.06B.
Analyst price targets range from a low of $19.00 to a high of $22.00, representing a 14% spread in expectations. The median target of $21.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 10 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SBRA trades at a trailing P/E of 31.3x and forward P/E of 29.7x. Analysts expect EPS to grow +10.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $26.61, with bear and bull scenarios of $16.76 and $35.06 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Real Estate stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+1.9%
Industry Consensus
Avg Forward P/E
114.5x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 WELLWelltower Inc. | $166.5B | $237.59 | $237.80 | +0.1% | Buy | 82.0x | 35 |
 VTRVentas, Inc. | $44.7B | $94.07 | $95.86 | +1.9% | Buy | 150.8x | 32 |
 OHIOmega Healthcare Investors, Inc. | $14.8B | $49.62 | $50.43 | +1.6% | Hold | 25.0x | 28 |
 LTCLTC Properties, Inc. | $2.0B | $39.23 | $36.00 | -8.2% | Hold | 20.9x | 22 |
 CTRECareTrust REIT, Inc. | $9.9B | $41.80 | $44.25 | +5.9% | Buy | 27.9x | 19 |
 NHINational Health Investors, Inc. | $3.7B | $77.31 | $82.83 | +7.1% | Hold | 21.9x | 19 |
 HRHealthcare Realty Trust Incorporated | $7.2B | $20.65 | $21.83 | +5.7% | Hold | — | 30 |
 DOCHealthpeak Properties, Inc. | $15.2B | $21.93 | $19.71 | -10.1% | Buy | 67.9x | 41 |
 GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
 CHCTCommunity Healthcare Trust Incorporated | $515M | $18.01 | $18.50 | +2.7% | Hold | 38.3x | 16 |
SBRA — Frequently Asked Questions
Quick answers to the most common questions about buying SBRA stock.
What is the SBRA stock price target for 2026?
The consensus price target for SBRA is $21, close to the current price of $20.06 (4.7% implied move). Based on 29 analyst estimates, the stock appears fairly valued near current levels.
Is SBRA a buy, sell, or hold?
SBRA has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $21 implies 4.7% upside from current levels.
Is SBRA stock overvalued or undervalued?
SBRA trades at a forward P/E of 29.7273x, representing a moderate valuation. With analysts targeting $21 (4.7% implied move), the stock appears close to fair value.
How high can SBRA stock go?
The most bullish Wall Street analyst has a price target of $22 for SBRA, while the most conservative target is $19. The consensus of $21 represents the median expectation. Our quantitative valuation model projects a bull case target of $35 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover SBRA stock?
SBRA is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SBRA stock forecast?
The 12-month SBRA stock forecast based on 29 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $19 (bear case) to $22 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $27, with bear/bull scenarios of $17/$35.
What is SBRA's fair value based on fundamentals?
Our quantitative valuation model calculates SBRA's fair value at $27 (base case), with a bear case of $17 and bull case of $35. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
What is SBRA's forward P/E ratio?
SBRA trades at a forward P/E ratio of 29.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SBRA stock?
SBRA appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $21 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SBRA price targets vary so much?
SBRA analyst price targets range from $19 to $22, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground. Our model's $17-$35 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare